Abingdon, United Kingdom

Michael Hugh Charlton

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2011-2012

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michael Hugh Charlton: Innovator in IKK-beta Inhibitors

Introduction

Michael Hugh Charlton is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for IKK-beta serine-threonine protein kinase. His work is crucial for advancing treatments for autoimmune and inflammatory diseases.

Latest Patents

Charlton holds 2 patents related to his innovative compounds. His latest patents include inhibitors of IKK-beta serine-threonine protein kinase, which are designed to target IkB kinase (IKK) activity. These compounds are formulated to be effective in treating various autoimmune and inflammatory conditions.

Career Highlights

Charlton is currently associated with Chroma Therapeutics Limited, where he continues to push the boundaries of medical research and innovation. His expertise in the field has positioned him as a key player in the development of therapeutic solutions.

Collaborations

Some of his notable coworkers include Stephen John Davies and Simon Christopher Hirst. Their collaborative efforts contribute to the advancement of research and development in their respective fields.

Conclusion

Michael Hugh Charlton's work in developing IKK-beta inhibitors showcases his commitment to improving healthcare through innovative solutions. His contributions are vital for the ongoing fight against autoimmune and inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…